Apimeds Pharmaceuticals US (APUS) EBITDA (2024 - 2026)
Apimeds Pharmaceuticals US (APUS) EBITDA from Mar 31, 2024 to Mar 31, 2026. The TTM Apimeds Pharmaceuticals US (APUS) EBITDA is -$25M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Apimeds Pharmaceuticals US (APUS) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +4278.57% |
Annual EBITDA change of Apimeds Pharmaceuticals US (APUS)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$12M | +2.18% |
| 2025 | -$12M | +837.80% |
| 2024 | -$1.27M | +71.62% |
| 2023 | -$740K | N/A |